[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597383":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":45,"responsibleParty":57,"collaborators":60,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":26,"eligibilityCriteria":75,"healthyVolunteers":72,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":26,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":89,"whyStopped":26,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Iguratimod plus low-dose rituximab","EXPERIMENTAL","Low-dose rituximab was used in combination with Iguratimod",[13,14],"Drug: Iguratimod","Drug: low-dose rituximab",{"label":16,"type":17,"description":18,"interventionNames":19},"Low-dose rituximab","ACTIVE_COMPARATOR","Low-dose rituximab alone",[14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Iguratimod","oral iguratimod at 25mg twice daily for 26 weeks",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"low-dose rituximab","rituximab 100mg once weekly for 6 weeks",[9,16],[32],{"name":33,"affiliation":34,"role":35},"Xiaohui Zhang","Peking University Institute of Hematology, Peking University People's Hospital","PRINCIPAL_INVESTIGATOR",[37,41],{"name":33,"role":38,"phone":39,"phoneExt":26,"email":40},"CONTACT","+8613522338836","zhangxh@bjmu.edu.cn",{"name":42,"role":38,"phone":43,"phoneExt":26,"email":44},"Qiusha Huang","+8613051816058","huangfuqs@163.com",[46],{"facility":47,"status":26,"city":48,"state":26,"zip":26,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":26},"Peking University Insititute of Hematology","Beijing","China","CN",{"type":52,"coordinates":53},"Point",[54,55],116.39723,39.9075,{"lat":55,"lon":54},{"type":35,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Xiao Hui Zhang","Vice president of Peking Univeristy Institute of Hematology",[61,64,66,68],{"name":62,"class":63},"Beijing Hospital","OTHER_GOV",{"name":65,"class":6},"Beijing Friendship Hospital",{"name":67,"class":6},"Navy General Hospital, Beijing",{"name":69,"class":6},"Beijing Tongren Hospital","100597383","phase-2-iguratimod-plus-low-dose-rituximab-vs-low-dose-rituximab-in-corticosteroid-resistant-or-relapsed-itp-100597383",false,"NCT07057778","Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP","Inclusion Criteria:\n\n* ITP confirmed by excluding other supervened causes of thrombocytopenia;\n* Platelet count of less than 30×10\\^9\u002FL at enrollment;\n* Patients who did not achieve a sustained response to treatment with full dose corticosteroids for a minimum duration of 4 weeks or who relapsed during steroid-tapering or after its discontinuation;\n\nExclusion Criteria:\n\n* Secondary immune thrombocytopenia (e.g., patients with HIV, HCV, Helicobacter pylori infection or patients with systemic lupus erythematosus);\n* Congestive heart failure;\n* Severe arrhythmia;\n* Nursing or pregnant women;\n* Aspartate aminotransferase and alanine transaminase levels ≥ 3×the upper limit of the normal threshold criteria;\n* Creatinine or serum bilirubin levels each 1•5 times or more than the normal range;\n* Active or previous malignancy;\n* Patients with other diseases were undergoing treatment with immunosuppressants;\n* Patients with ITP had received rituximab;","ALL","18 Years","70 Years",{"count":80,"type":81},120,"ESTIMATED","INTERVENTIONAL",[84],"PHASE2","Randomized, open-label, multicentre study to assess the efficacy and safety of the combination of low-dose rituximab and Iguratimod in patients with steroid-resistant\u002Frelapsed ITP.",[87],"Immune Thrombocytopenia (ITP)",[23],"NOT_YET_RECRUITING","2025-06-30",{"date":92,"type":93},"2025-07-10","ACTUAL",{"date":95,"type":81},"2025-07-01",{"date":97,"type":81},"2027-07-01",{"name":5,"class":6},1]